oncor inc. , gaithersburg , md. , said 0 it received approval from the u.s. food and drug administration to market a genetic test that will assist in diagnosis and treatment of leukemia and lymph cancer . the b\/t gene rearrangement test is more accurate than existing tests for diagnosing the type of cancer , whether it has spread or whether there is a recurrence following treatment , said 0 oncor president stephen turner . mr. turner said 0 the test initially will be used in conjunction with biopsies and other tests , but eventually might become the benchmark for tumor analysis . mr. turner said 0 the test will be shipped in 45 days to hospitals and clinical laboratories . dr. wyndham wilson , a cancer treatment specialist at the national cancer institute , said 0 the test is widely used in research centers but is n't having a major impact because it is only occasionally useful in choosing the most effective treatment . but the test may prove to be more sensitive in determining whether a tumor has spread or returned following treatment , dr. wilson said 0 . `` we do n't know yet how useful it 's going to be , '' he said . oncor , a six-year-old developer of genetic medical tests , projects that the cancer test will help it to post its first-ever profit during the first quarter of 1990 , mr. turner said 0 . the company will charge $ 35 for a test and projects about $ 2 million in revenue from the test during the first 12 months of marketing , he said 0 .